OliX, Icure IPOs Test Korean Biotech Sentiment Amid Samsung Uncertainties
OliX Pharmaceuticals and Icure are poised to be first biotech firms to launch IPOs this year amid uncertainties over ongoing accounting issues at Samsung BioLogics and possible tougher accounting reviews on IPO seekers.
You may also be interested in...
In a move to harmonize the pharma and biotech industry's accounting practices with global trends, South Korea’s financial authority will examine companies’ R&D cost-related accounting to check for possible ‘distortions’.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.